|
GOLGA7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.77755596300722E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.39450023645327E-10 |
| Normal-vs-Stage2 |
1.01299999499815E-08 |
| Normal-vs-Stage3 |
3.59712259978551E-13 |
| Normal-vs-Stage4 |
1.63957736276643E-12 |
| Stage1-vs-Stage2 |
4.322400E-01 |
| Stage1-vs-Stage3 |
1.272130E-02 |
| Stage1-vs-Stage4 |
1.609370E-04 |
| Stage2-vs-Stage3 |
2.365400E-01 |
| Stage2-vs-Stage4 |
1.410190E-02 |
| Stage3-vs-Stage4 |
1.442960E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.29936078458104E-12 |
| Normal-vs-AfricanAmerican |
4.86140000000024E-06 |
| Normal-vs-Asian |
4.52659999483629E-08 |
| Caucasian-vs-AfricanAmerican |
7.648600E-01 |
| Caucasian-vs-Asian |
5.211400E-01 |
| AfricanAmerican-vs-Asian |
8.623000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.98716607005645E-12 |
| Normal-vs-Female |
2.24259499859158E-11 |
| Male-vs-Female |
2.225800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.78910003373534E-09 |
| Normal-vs-Age(41-60Yrs) |
5.19917442431961E-13 |
| Normal-vs-Age(61-80Yrs) |
2.97084579159446E-12 |
| Normal-vs-Age(81-100Yrs) |
4.247100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.611900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.251900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.408200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.692800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.947800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.153800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.673050E-01 |
| Classical-VS-Follicular |
9.518000E-01 |
| Classical-VS-Other |
4.999600E-01 |
| Classical-VS-Normal |
5.17059728366576E-11 |
| Tall-VS-Follicular |
2.589000E-01 |
| Tall-VS-Other |
9.789800E-01 |
| Tall-VS-Normal |
1.178899999843E-08 |
| Follicular-VS-Other |
5.724400E-01 |
| Follicular-VS-Normal |
1.13549999958273E-07 |
| Other-VS-Normal |
1.598150E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.9367952514292E-11 |
| Normal-vs-N1 |
1.28674848554056E-12 |
| N0-vs-N1 |
3.447900E-02 |
|
|
